A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors

Md Maksudul Alam, Sneha Lal, Keely E FitzGerald, Li Zhang, Md Maksudul Alam, Sneha Lal, Keely E FitzGerald, Li Zhang

Abstract

Since Otto Warburg made the first observation that tumor cells exhibit altered metabolism and bioenergetics in the 1920s, many scientists have tried to further the understanding of tumor bioenergetics. Particularly, in the past decade, the application of the state-of the-art metabolomics and genomics technologies has revealed the remarkable plasticity of tumor metabolism and bioenergetics. Firstly, a wide array of tumor cells have been shown to be able to use not only glucose, but also glutamine for generating cellular energy, reducing power, and metabolic building blocks for biosynthesis. Secondly, many types of cancer cells generate most of their cellular energy via mitochondrial respiration and oxidative phosphorylation. Glutamine is the preferred substrate for oxidative phosphorylation in tumor cells. Thirdly, tumor cells exhibit remarkable versatility in using bioenergetics substrates. Notably, tumor cells can use metabolic substrates donated by stromal cells for cellular energy generation via oxidative phosphorylation. Further, it has been shown that mitochondrial transfer is a critical mechanism for tumor cells with defective mitochondria to restore oxidative phosphorylation. The restoration is necessary for tumor cells to gain tumorigenic and metastatic potential. It is also worth noting that heme is essential for the biogenesis and proper functioning of mitochondrial respiratory chain complexes. Hence, it is not surprising that recent experimental data showed that heme flux and function are elevated in non-small cell lung cancer (NSCLC) cells and that elevated heme function promotes intensified oxygen consumption, thereby fueling tumor cell proliferation and function. Finally, emerging evidence increasingly suggests that clonal evolution and tumor genetic heterogeneity contribute to bioenergetic versatility of tumor cells, as well as tumor recurrence and drug resistance. Although mutations are found only in several metabolic enzymes in tumors, diverse mutations in signaling pathways and networks can cause changes in the expression and activity of metabolic enzymes, which likely enable tumor cells to gain their bioenergetic versatility. A better understanding of tumor bioenergetics should provide a more holistic approach to investigate cancer biology and therapeutics. This review therefore attempts to comprehensively consider and summarize the experimental data supporting our latest view of cancer bioenergetics.

Keywords: Glutamine; Heme; Hemoprotein; Metabolic mutations; Mitochondrial respiration; Mitochondrial transfer; Oxidative phosphorylation; Tumor bioenergetics; Tumor heterogeneity.

Figures

Fig. 1
Fig. 1
The metabolic steps of glycolysis and TCA cycle. The steps involved in glycolysis and TCA cycle are demarcated separately. ATP/GTP utilization or synthesis is shown in green, while NAD+/NADH and FAD/FADH2 are shown in red. Also indicated are the numbers of NADH, FADH2, and ATP/GTP generated when one molecule of glucose is consumed following glycolysis, TCA cycle, and oxidative phosphorylation. Abbreviations: Glucose-6-P glucose 6-phosphate, Fructose-6-P fructose 6-phosphate, Fructose -1,6-bis-P fructose 1,6-bisphosphate, Dihydroxyacetone-P dihydroxyacetone phosphate, Glyceraldehyde-3-P glyceraldehyde 3-phosphate, 1,3-Bis-P-glycerate 1,3-bisphosphoglycerate, 3-P-Glycerate 3-phosphoglycerate, 2-P-Glycerate 2-phosphoglycerate, OXPHOS oxidative phosphorylation
Fig. 2
Fig. 2
Metabolic fuels for tumor cells. Tumor cells are able to use a variety of bioenergetic substrates, including glutamine, glucose, fatty acids (FA), ketone bodies, and acetate (highlighted by red boxes). These substrates can be provided by stromal cells in the microenvironment. Much of the cellular energy for tumor cells is likely generated by TCA cycle coupled to oxidative phosphorylation. The pathways for the generation and metabolism of these substrates are outlined. Notably, glutamine and glucose can also provide building blocks for the synthesis of many biomolecules. Also indicated in pink are the metabolic enzymes whose mutations are found in various tumors and the accumulated oncometabolites in these tumors
Fig. 3
Fig. 3
The function and composition of mitochondrial OXPHOS complexes I–V. Shown here are the directions of electron and proton transport by the OXPHOS complexes. Also indicated are the origins of DNA encoding the subunits and the hemes needed for complexes II–IV. nDNA nuclear DNA, mtDNA mitochondrial DNA
Fig. 4
Fig. 4
The signaling and structural functions of heme in human cells. Human cells can synthesize heme de novo in mitochondria (the first and rate-limiting enzyme is ALAS, 5-aminolevulinate synthase) or import heme via heme transporters, such as HRG1 and HCP1. Inside cells, heme serves as a prosthetic group in numerous enzymes and proteins that transport, store, or use oxygen, such as mitochondrial cytochromes and cytochrome P450. Additionally, heme directly regulates the activity of diverse cellular signaling and regulatory molecules, such as Bach1, Rev-ERBα, and Rev-ERBβ (transcriptional regulators), as well as DGCR8 (an essential miRNA processing factor) in the nucleus. Heme also regulates HRI (the heme-regulated inhibitor kinase controlling protein synthesis) and the Ras-ERK signaling pathway in the cytoplasm. Furthermore, heme regulates the activity of the NMDA receptor, the SloBK potassium channel, and the ENaCs sodium channel on the cell membrane

References

    1. Pasteur L. Mémoire sur la Fermentation Alcoolique. Paris: Imprimerie de Mallet-Bachelier; 1860.
    1. Buchner T. Uber ein phosphat ubertragendes Garungsferment. Biochim Biophys Acta. 1947;1:292–314. doi: 10.1016/0006-3002(47)90143-1.
    1. von Szent-Gyorgyi A. Zellatmung IV. Mitteilung: Uber den Oxydationsmechanismus der Kartoffeln. Biochemische Zeitschrift. 1925;162:399–412.
    1. von Szent-Gyorgyi A. Zellatmung V. Mitteilung: Uber den Oxydationsmechanismus einiger Pflanzen. Biochemische Zeitschrift. 1927;181:425–432.
    1. Gozsy B, Szent-Gyorgyi A (1934) Uber den Mechanismus der Hauptatmung des Taubenbrustmuskels. Hoppe-Seyler’s Zeitschrift fur physiologische Chemie 224(1–2):1–10
    1. Annau E, Banga I, Gozsy B, Huszak St, Laki K, Straub FB, Szent-Gyorgyi A (1935) Uber die Bedeutung der Fumarsaure fur die Tierische Gewebsatmung: Einleitung Ubersicht Methoden. Hoppe-Seyler’s Zeitschrift fur physiologische Chemie 236(1):1–20
    1. Annau E, Banga I, Blazso A, Bruckner V, Laki K, Straub FB, Szent-Gyorgyi A (1936) Uber die Bedeutung der Fumarsaure fur die Tierische GewebsatmungEinleitung, Ubersicht, Methoden III Mitteilung. Hoppe-Seyler’s Zeitschrift fur physiologische Chemie 244:105–116
    1. Lipmann F. On chemistry and function of coenzyme A. Bacteriol Rev. 1953;17(1):1–16.
    1. Krebs HA. The citric acid cycle and the Szent-Gyorgyi cycle in pigeon breast muscle. Biochem J. 1940;34(5):775–779. doi: 10.1042/bj0340775.
    1. Dickens F, McIlwain H, Neuberger A, Norris FW, O’Brien JRP, Young FG. Biochemistry. Annu Rep Prog Chem. 1944;41:230–271. doi: 10.1039/ar9444100230.
    1. Boyer PD, Ariki M. 18O-probes of phosphoenzyme formation and cooperativity with sarcoplasmic reticulum ATPase. Fed Proc. 1980;39(7):2410–2414.
    1. Boyer PD, Cross RL, Momsen W. A new concept for energy coupling in oxidative phosphorylation based on a molecular explanation of the oxygen exchange reactions. Proc Natl Acad Sci. 1973;70(10):2837–2839. doi: 10.1073/pnas.70.10.2837.
    1. Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–337. doi: 10.1038/nrc3038.
    1. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–530. doi: 10.1085/jgp.8.6.519.
    1. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi: 10.1126/science.123.3191.309.
    1. Wenner CE, Weinhouse S. Metabolism of neoplastic tissue III Diphosphopyridine nucleotide requirements for oxidations by mitochondria of neoplastic and non-neoplastic tissues. Cancer Res. 1953;13(1):21–26.
    1. Weinhouse S. On respiratory impairment in cancer cells. Science. 1956;124(3215):267–269. doi: 10.1126/science.124.3215.267.
    1. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem. 1979;254(8):2669–2676.
    1. Anastasiou D, Cantley LC. Breathless cancer cells get fat on glutamine. Cell Res. 2012;22(3):443–446. doi: 10.1038/cr.2012.5.
    1. DeBerardinis RJ, Cheng T. Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29(3):313–324. doi: 10.1038/onc.2009.358.
    1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297–308. doi: 10.1016/j.ccr.2012.02.014.
    1. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678–3684. doi: 10.1172/JCI69600.
    1. Kovacevic Z, Morris HP. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res. 1972;32(2):326–333.
    1. Lanks KW, Hitti IF, Chin NW. Substrate utilization for lactate and energy production by heat-shocked L929 cells. J Cell Physiol. 1986;127(3):451–456. doi: 10.1002/jcp.1041270315.
    1. Goossens V, Grooten J, Fiers W. The oxidative metabolism of glutamine. A modulator of reactive oxygen intermediate-mediated cytotoxicity of tumor necrosis factor in L929 fibrosarcoma cells. J Biol Chem. 1996;271(1):192–196. doi: 10.1074/jbc.271.1.192.
    1. Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol. 2013;9:712. doi: 10.1038/msb.2013.65.
    1. Hooda J, Alam MM, Zhang L. Evaluating the Association of Heme and Heme Metabolites with Lung Cancer Bioenergetics and Progression. Metabolomics. 2015;5(3):1000150.
    1. Vander Heiden MG Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi: 10.1126/science.1160809.
    1. Griguer CE, Oliva CR, Gillespie GY. Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol. 2005;74(2):123–133. doi: 10.1007/s11060-004-6404-6.
    1. van den Heuvel AP, Jing J, Wooster RF, Bachman KE. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol Ther. 2012;13(12):1185–1194. doi: 10.4161/cbt.21348.
    1. Bergstrom J, Furst P, Noree LO, Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol. 1974;36(6):693–697. doi: 10.1152/jappl.1974.36.6.693.
    1. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A. 2011;108(49):19611–19616. doi: 10.1073/pnas.1117773108.
    1. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481(7381):380–384. doi: 10.1038/nature10602.
    1. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481(7381):385–388. doi: 10.1038/nature10642.
    1. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–105. doi: 10.1038/nature12040.
    1. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491(7424):364–373. doi: 10.1038/nature11706.
    1. Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52(4):585–589. doi: 10.1016/j.plipres.2013.08.005.
    1. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–777. doi: 10.1038/nrc2222.
    1. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F] fluorocholine and [18 F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168(1):273–280. doi: 10.1016/S0022-5347(05)64906-3.
    1. Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res. 2010;30(2):369–374.
    1. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, et al. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate. 2005;63(4):316–323. doi: 10.1002/pros.20177.
    1. Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, et al. Acetate dependence of tumors. Cell. 2014;159(7):1591–1602. doi: 10.1016/j.cell.2014.11.020.
    1. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603–1614. doi: 10.1016/j.cell.2014.11.025.
    1. Berridge MV, Herst PM, Tan AS. Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion. 2010;10(6):584–588. doi: 10.1016/j.mito.2010.08.002.
    1. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010;9(17):3506–3514. doi: 10.4161/cc.9.17.12731.
    1. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984–4001. doi: 10.4161/cc.8.23.10238.
    1. Icard P, Kafara P, Steyaert JM, Schwartz L, Lincet H. The metabolic cooperation between cells in solid cancer tumors. Biochim Biophys Acta. 2014;1846(1):216–225.
    1. Lisanti MP, Martinez-Outschoorn UE, Sotgia F. Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery. Cell Cycle. 2013;12(17):2723–2732. doi: 10.4161/cc.25695.
    1. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 2014;25:47–60. doi: 10.1016/j.semcancer.2014.01.005.
    1. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, et al. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biol Ther. 2011;12(12):1085–1097. doi: 10.4161/cbt.12.12.18671.
    1. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–1503. doi: 10.1038/nm.2492.
    1. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, et al. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the “reverse Warburg effect” in positive lymph node tissue. Cell Cycle. 2012;11(7):1445–1454. doi: 10.4161/cc.19841.
    1. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in cancer. J Mol Med (Berl). 2011;89(3):213–220. doi: 10.1007/s00109-011-0728-4.
    1. Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18(20):5562–5571. doi: 10.1158/1078-0432.CCR-12-1773.
    1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. doi: 10.1126/science.1164382.
    1. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–1066. doi: 10.1056/NEJMoa0903840.
    1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597–602. doi: 10.1007/s00401-008-0455-2.
    1. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al. IDH1 mutations at residue p. R132 [IDH1(R132)] occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009;30(1):7–11. doi: 10.1002/humu.20937.
    1. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–474. doi: 10.1007/s00401-009-0561-9.
    1. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–1153. doi: 10.2353/ajpath.2009.080958.
    1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773. doi: 10.1056/NEJMoa0808710.
    1. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010;115(14):2749–2754. doi: 10.1182/blood-2009-11-253070.
    1. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16(9):387–397. doi: 10.1016/j.molmed.2010.07.002.
    1. Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat. 2010;31(3):E1186–E1199. doi: 10.1002/humu.21201.
    1. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339–344. doi: 10.1084/jem.20092506.
    1. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, et al. Molecular alterations of the IDH1 gene in AML: a children’s oncology group and southwest oncology group study. Leukemia. 2010;24(5):909–913. doi: 10.1038/leu.2010.56.
    1. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24(7):1302–1309. doi: 10.1038/leu.2010.113.
    1. Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010;28(14):2356–2364. doi: 10.1200/JCO.2009.27.6899.
    1. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–234. doi: 10.1016/j.ccr.2010.01.020.
    1. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334–343. doi: 10.1002/path.2913.
    1. Pansuriya TC, van Eijk R, d’Adamo P, van Ruler MA, Kuijjer ML, Oosting J, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43(12):1256–1261. doi: 10.1038/ng.1004.
    1. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–79. doi: 10.1634/theoncologist.2011-0386.
    1. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32(25):3091–3100. doi: 10.1038/onc.2012.315.
    1. Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol. 2010;163(5):747–755. doi: 10.1530/EJE-10-0473.
    1. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun. 2010;393(3):555–559. doi: 10.1016/j.bbrc.2010.02.095.
    1. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125(2):353–355. doi: 10.1002/ijc.24379.
    1. Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2010;95(3):1274–1278. doi: 10.1210/jc.2009-2170.
    1. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. doi: 10.1038/nature08617.
    1. Kalinina J, Carroll A, Wang L, Yu Q, Mancheno DE, Wu S, et al. Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med (Berl). 2012;90(10):1161–1171. doi: 10.1007/s00109-012-0888-x.
    1. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116):1165. doi: 10.1126/scitranslmed.3002796.
    1. Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta. 2011;1807(11):1432–1443. doi: 10.1016/j.bbabio.2011.07.003.
    1. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005;14(15):2231–2239. doi: 10.1093/hmg/ddi227.
    1. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26(12):1326–1338. doi: 10.1101/gad.191056.112.
    1. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406–410. doi: 10.1038/ng849.
    1. Campione E, Terrinoni A, Orlandi A, Codispoti A, Melino G, Bianchi L, et al. Cerebral cavernomas in a family with multiple cutaneous and uterine leiomyomas associated with a new mutation in the fumarate hydratase gene. J Invest Dermatol. 2007;127(9):2271–2273. doi: 10.1038/sj.jid.5700851.
    1. Carvajal-Carmona LG, Alam NA, Pollard PJ, Jones AM, Barclay E, Wortham N, et al. Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. J Clin Endocrinol Metab. 2006;91(8):3071–3075. doi: 10.1210/jc.2006-0183.
    1. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szymanska A, et al. Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet. 2006;14(7):880–883. doi: 10.1038/sj.ejhg.5201630.
    1. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324(5924):261–265. doi: 10.1126/science.1170944.
    1. Yang H, Xiong Y, Guan K. Metabolic alteration in tumorigenesis. Sci China Life Sci. 2013;56(12):1067–1075. doi: 10.1007/s11427-013-4549-2.
    1. Loewe R, Valero T, Kremling S, Pratscher B, Kunstfeld R, Pehamberger H, et al. Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res. 2006;66(24):11888–11896. doi: 10.1158/0008-5472.CAN-06-2397.
    1. Valero T, Steele S, Neumuller K, Bracher A, Niederleithner H, Pehamberger H, et al. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis. J Invest Dermatol. 2010;130(4):1087–1094. doi: 10.1038/jid.2009.368.
    1. Yamazoe Y, Tsubaki M, Matsuoka H, Satou T, Itoh T, Kusunoki T, et al. Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol Int. 2009;33(10):1087–1094. doi: 10.1016/j.cellbi.2009.06.027.
    1. Sudarshan S, Shanmugasundaram K, Naylor SL, Lin S, Livi CB, O’Neill CF, et al. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2alpha accumulation and promotes migration and invasion. PLoS One. 2011;6(6):e21037. doi: 10.1371/journal.pone.0021037.
    1. Kushnareva Y, Murphy AN, Andreyev A. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P) + oxidation-reduction state. Biochem J. 2002;368(2):545–553. doi: 10.1042/bj20021121.
    1. Sullivan LB, Chandel NS. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2014;2:17. doi: 10.1186/2049-3002-2-17.
    1. McCord JM. The evolution of free radicals and oxidative stress. Am J Med. 2000;108(8):652–659. doi: 10.1016/S0002-9343(00)00412-5.
    1. Hansen JM, Go YM, Jones DP. Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol Toxicol. 2006;46:215–234. doi: 10.1146/annurev.pharmtox.46.120604.141122.
    1. Genova ML, Pich MM, Biondi A, Bernacchia A, Falasca A, Bovina C, et al. Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Exp Biol Med. 2003;228(5):506–513. doi: 10.1177/15353702-0322805-14.
    1. Lander HM. An essential role for free radicals and derived species in signal transduction. Faseb J. 1997;11(2):118–124. doi: 10.1096/fasebj.11.2.9039953.
    1. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 2012;16(11):1295–1322. doi: 10.1089/ars.2011.4414.
    1. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995;18(4):775–794. doi: 10.1016/0891-5849(94)00198-S.
    1. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991;51(3):794–798.
    1. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320(5876):661–664. doi: 10.1126/science.1156906.
    1. Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer. 2014;14(11):709–721. doi: 10.1038/nrc3803.
    1. Singh KK. Mitochondria damage checkpoint, aging, and cancer. Ann N Y Acad Sci. 2006;1067:182–190. doi: 10.1196/annals.1354.022.
    1. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 2007;96(9):2181–2196. doi: 10.1002/jps.20874.
    1. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev. 2009;61(4):290–302. doi: 10.1016/j.addr.2009.02.005.
    1. Guppy M, Leedman P, Zu X, Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J. 2002;364(Pt 1):309–315. doi: 10.1042/bj3640309.
    1. Rodriguez-Enriquez S, Torres-Marquez ME, Moreno-Sanchez R. Substrate oxidation and ATP supply in AS-30D hepatoma cells. Arch Biochem Biophys. 2000;375(1):21–30. doi: 10.1006/abbi.1999.1582.
    1. Rodriguez-Enriquez S, Vital-Gonzalez PA, Flores-Rodriguez FL, Marin-Hernandez A, Ruiz-Azuara L, Moreno-Sanchez R. Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells. Toxicol Appl Pharmacol. 2006;215(2):208–217. doi: 10.1016/j.taap.2006.02.005.
    1. Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313(3):459–465. doi: 10.1016/j.bbrc.2003.11.136.
    1. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628–632. doi: 10.1038/nature13611.
    1. LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16(10):992–1003. doi: 10.1038/ncb3039.
    1. Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, et al. NF-kappaB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol. 2011;13(10):1272–1279. doi: 10.1038/ncb2324.
    1. Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 2015;21(1):81–94. doi: 10.1016/j.cmet.2014.12.003.
    1. Strakova A, Murchison EP. The cancer which survived: insights from the genome of an 11000 year-old cancer. Curr Opin Genet Dev. 2015;30:49–55. doi: 10.1016/j.gde.2015.03.005.
    1. Rebbeck CA, Leroi AM, Burt A. Mitochondrial capture by a transmissible cancer. Science. 2011;331(6015):303. doi: 10.1126/science.1197696.
    1. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol. 2010;5:297–348. doi: 10.1146/annurev.pathol.4.110807.092314.
    1. Efremov RG, Baradaran R, Sazanov LA. The architecture of respiratory complex I. Nature. 2010;465(7297):441–445. doi: 10.1038/nature09066.
    1. Efremov RG, Sazanov LA. Structure of the membrane domain of respiratory complex I. Nature. 2011;476(7361):414–420. doi: 10.1038/nature10330.
    1. Kim HJ, Khalimonchuk O, Smith PM, Winge DR. Structure, function, and assembly of heme centers in mitochondrial respiratory complexes. Biochim Biophys Acta. 2012;1823(9):1604–1616. doi: 10.1016/j.bbamcr.2012.04.008.
    1. Bock KW, De Matteis F, Aldridge WN. Heme and Hemoproteins. New York: Springer-Verlag; 1978.
    1. Padmanaban G, Venkateswar V, Rangarajan PN. Haem as a multifunctional regulator. Trends Biochem Sci. 1989;14(12):492–496. doi: 10.1016/0968-0004(89)90182-5.
    1. Chen JJ, London IM. Regulation of protein synthesis by heme-regulated eIF-2 alpha kinase. Trends Biochem Sci. 1995;20(3):105–108. doi: 10.1016/S0968-0004(00)88975-6.
    1. Zhang L (2011) HEME BIOLOGY: The Secret Life of Heme in Regulating Diverse Biological Processes: World Scientific
    1. Hooda J, Shah A, Zhang L. Heme, an essential nutrient from dietary proteins, critically impacts diverse physiological and pathological processes. Nutrients. 2014;6(3):1080–1102. doi: 10.3390/nu6031080.
    1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaudt AL, Sly WS, Valle D, Barton C, Kinzler KW, editors. The metabolic and molecular bases of inherited disease. 3. New York: The McGraw-Hill Companies Inc; 2001. pp. 2991–3062.
    1. Sassa S. Novel effects of heme and heme-related compounds in biological systems. Current Med Chem. 1996;3:273–290.
    1. Suzuki H, Tashiro S, Hira S, Sun J, Yamazaki C, Zenke Y, et al. Heme regulates gene expression by triggering Crm1-dependent nuclear export of Bach1. EMBO J. 2004;23(13):2544–2553. doi: 10.1038/sj.emboj.7600248.
    1. Zenke-Kawasaki Y, Dohi Y, Katoh Y, Ikura T, Ikura M, Asahara T, et al. Heme induces ubiquitination and degradation of the transcription factor Bach1. Mol Cell Biol. 2007;27(19):6962–6971. doi: 10.1128/MCB.02415-06.
    1. Hira S, Tomita T, Matsui T, Igarashi K, Ikeda-Saito M. Bach1, a heme-dependent transcription factor, reveals presence of multiple heme binding sites with distinct coordination structure. IUBMB Life. 2007;59(8–9):542–551. doi: 10.1080/15216540701225941.
    1. Uma S, Matts RL, Guo Y, White S, Chen JJ. The N-terminal region of the heme-regulated eIF2alpha kinase is an autonomous heme binding domain. Eur J Biochem. 2000;267(2):498–506. doi: 10.1046/j.1432-1327.2000.01021.x.
    1. Rafie-Kolpin M, Chefalo PJ, Hussain Z, Hahn J, Uma S, Matts RL, et al. Two heme-binding domains of heme-regulated eukaryotic initiation factor-2alpha kinase. N terminus and kinase insertion. J Biol Chem. 2000;275(7):5171–5178. doi: 10.1074/jbc.275.7.5171.
    1. Sengupta A, Hon T, Zhang L. Heme deficiency suppresses the expression of key neuronal genes and causes neuronal cell death. Brain Res Mol Brain Res. 2005;137(1–2):23–30. doi: 10.1016/j.molbrainres.2005.02.007.
    1. Zhu Y, Hon T, Ye W, Zhang L. Heme deficiency interferes with the Ras-mitogen-activated protein kinase signaling pathway and expression of a subset of neuronal genes. Cell Growth Differ. 2002;13(9):431–439.
    1. Chernova T, Nicotera P, Smith AG. Heme deficiency is associated with senescence and causes suppression of N-methyl-D-aspartate receptor subunits expression in primary cortical neurons. Mol Pharmacol. 2006;69(3):697–705.
    1. Chernova T, Steinert JR, Guerin CJ, Nicotera P, Forsythe ID, Smith AG. Neurite degeneration induced by heme deficiency mediated via inhibition of NMDA receptor-dependent extracellular signal-regulated kinase 1/2 activation. J Neurosci. 2007;27(32):8475–8485. doi: 10.1523/JNEUROSCI.0792-07.2007.
    1. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol. 2007;14(12):1207–1213. doi: 10.1038/nsmb1344.
    1. Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, Reid RA, et al. Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science. 2007;318(5857):1786–1789. doi: 10.1126/science.1150179.
    1. Faller M, Matsunaga M, Yin S, Loo JA, Guo F. Heme is involved in microRNA processing. Nat Struct Mol Biol. 2007;14(1):23–29. doi: 10.1038/nsmb1182.
    1. Tang XD, Xu R, Reynolds MF, Garcia ML, Heinemann SH, Hoshi T. Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels. Nature. 2003;425(6957):531–535. doi: 10.1038/nature02003.
    1. Wang S, Publicover S, Gu Y. An oxygen-sensitive mechanism in regulation of epithelial sodium channel. Proc Natl Acad Sci U S A. 2009;106(8):2957–2962. doi: 10.1073/pnas.0809100106.
    1. Sahoo N, Goradia N, Ohlenschlager O, Schonherr R, Friedrich M, Plass W, et al. Heme impairs the ball-and-chain inactivation of potassium channels. Proc Natl Acad Sci U S A. 2013;110(42):E4036–E4044. doi: 10.1073/pnas.1313247110.
    1. Weinbach EC, Ebert PS. Effects of succinylacetone on growth and respiration of L1210 leukemia cells. Cancer Lett. 1985;26(3):253–259. doi: 10.1016/0304-3835(85)90048-5.
    1. Ye WZ, Zhang L. Heme controls the expression of cell cycle regulators and cell proliferation in HeLa Cells. Biochem Biophys Res Commun. 2004;315:546–554. doi: 10.1016/j.bbrc.2004.01.092.
    1. Ye WZ, Zhang L. Heme Deficiency Causes Apoptosis But Does Not Increase ROS Generation in HeLa Cells. Biochem Biophys Res Commun. 2004;319:1065–1071. doi: 10.1016/j.bbrc.2004.05.089.
    1. Hooda J, Cadinu D, Alam MM, Shah A, Cao TM, Sullivan LA, et al. Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells. PLoS ONE. 2013;8(5):e63402. doi: 10.1371/journal.pone.0063402.
    1. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004;64(24):9027–9034. doi: 10.1158/0008-5472.CAN-04-3703.
    1. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 2007;446(7137):815–819. doi: 10.1038/nature05697.
    1. Latunde-Dada GO, Takeuchi K, Simpson RJ, McKie AT. Haem carrier protein 1 (HCP1): expression and functional studies in cultured cells. FEBS Lett. 2006;580(30):6865–6870. doi: 10.1016/j.febslet.2006.11.048.
    1. Rajagopal A, Rao AU, Amigo J, Tian M, Upadhyay SK, Hall C, et al. Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins. Nature. 2008;453(7198):1127–1131. doi: 10.1038/nature06934.
    1. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337. doi: 10.1038/nature11252.
    1. Network CGA. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–322. doi: 10.1038/nature12965.
    1. Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi: 10.1038/nature11412.
    1. Network CGA. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550. doi: 10.1038/nature13385.
    1. Network CGA. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. doi: 10.1056/NEJMoa1301689.
    1. Gruber M, Wu CJ. Evolving understanding of the CLL genome. Semin Hematol. 2014;51(3):177–187. doi: 10.1053/j.seminhematol.2014.05.004.
    1. Guieze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015;126(4):445–453. doi: 10.1182/blood-2015-02-585042.
    1. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16(7):e342–e351. doi: 10.1016/S1470-2045(15)00077-7.
    1. Chang DK, Grimmond SM, Biankin AV. Pancreatic cancer genomics. Curr Opin Genet Dev. 2014;24:74–81. doi: 10.1016/j.gde.2013.12.001.
    1. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15–26. doi: 10.1016/j.ccell.2014.12.001.
    1. De Sousa EMF, Vermeulen L, Fessler E, Medema JP. Cancer heterogeneity–a multifaceted view. EMBO Rep. 2013;14(8):686–695. doi: 10.1038/embor.2013.92.
    1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi: 10.1126/science.1235122.
    1. Wyatt AW, Mo F, Wang Y, Collins CC. The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl. 2013;15(3):301–308. doi: 10.1038/aja.2013.13.
    1. Shibata D. Cancer. Heterogeneity and tumor history. Science. 2012;336(6079):304–305.
    1. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi: 10.1056/NEJMoa1113205.
    1. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405. doi: 10.1038/nature11547.
    1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi: 10.1038/nature12477.
    1. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–1117. doi: 10.1038/nature09515.
    1. Ellsworth RE, Toro AL, Blackburn HL, Decewicz A, Deyarmin B, Mamula KA, et al. Molecular Heterogeneity in Primary Breast Carcinomas and Axillary Lymph Node Metastases Assessed by Genomic Fingerprinting Analysis. Cancer Growth Metastasis. 2015;8:15–24. doi: 10.4137/CGM.S29490.
    1. Leiserson MD, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet. 2015;47(2):106–114. doi: 10.1038/ng.3168.
    1. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–28. doi: 10.1126/science.959840.
    1. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346(6206):251–256. doi: 10.1126/science.1253462.
    1. Zhang J, Fujimoto J, Wedge DC, Song X, Seth S, Chow CW, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346(6206):256–259. doi: 10.1126/science.1256930.
    1. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103(8):1139–1143. doi: 10.1038/sj.bjc.6605912.
    1. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–313. doi: 10.1038/nature10762.
    1. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13(11):795–806. doi: 10.1038/nrg3317.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe